Screener / SEC EDGAR /CIK 0000818686 /10-K filed Feb 3, 2026, compared with Feb 5, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Pharmaceuticals

Teva Pharmaceutical Industries Ltd TEVA

Employees
33,950
Headquarters
Tel Aviv
CEO
Richard D. Francis
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $17.3B through the costs to a net profit of $1.4B · income statement of the 10-K

12% operating margin
Revenue to Gross profit: $8.9BRevenue to Cost of revenue: $8.3BGross profit to Operating profit: $2.2BGross profit to Operating expenses: $6.8BOperating profit to Net profit: $1.4BOperating profit to Interest, tax, other: $747.0MOperating expenses to R&D: $1.0BOperating expenses to Sales, admin & other: $5.8B Revenue: $17.3B REVENUE $17.3B +4% Y/Y Gross profit: $8.9B · 52% margin GROSS PROFIT $8.9B 52% margin · +11% Y/Y Cost of revenue: $8.3B · 48% of revenue COST OF REVENUE $8.3B 48% of revenue Operating profit: $2.2B · 12% margin OPERATING PROFIT $2.2B 12% margin Operating expenses: $6.8B · 39% of revenue OPERATING EXPENSES $6.8B 39% of revenue Net profit: $1.4B · 8% margin NET PROFIT $1.4B 8% margin Interest, tax, other: $747.0M · 4% of revenue INTEREST, TAX, OTHER $747.0M 4% of revenue R&D: $1.0B · 6% of revenue R&D $1.0B 6% of revenue Sales, admin & other: $5.8B · 33% of revenue SALES, ADMIN & OTHER $5.8B 33% of revenue
Gross profit $8.9B 52% margin · +11% Y/Y
Operating profit $2.2B 12% margin
Net profit $1.4B 8% margin
The full income statement, year by year

TEVA among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 4.3%, above 24% of 154 peers (their median 10.5%) REVENUE GROWTH 4.3% · above 24% Gross margin: 53.5%, above 33% of 107 peers (their median 63.8%) GROSS MARGIN 53.5% · above 33% Operating margin: 8.3%, above 46% of 138 peers (their median 10.2%) OPERATING MARGIN 8.3% · above 46% Net margin: 2.9%, above 41% of 153 peers (their median 6.8%) NET MARGIN 2.9% · above 41% FCF margin: 7.2%, above 40% of 144 peers (their median 10.1%) FCF MARGIN 7.2% · above 40% Return on capital: 10.0%, above 57% of 89 peers (their median 9.0%) RETURN ON CAPITAL 10.0% · above 57%
TEVA Peer median Below the median

What changed

14 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 3, 2026 against Feb 5, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +21.2% ($3.1B to $3.7B) vs revenue +4.3% ($16.5B to $17.3B), +16.9 pts apart
  • Critical audit matters changed
    New this year: Long-lived assets impairment assessment - Manufacturing facility in Europe (“Asset Group”) (“As described in Notes 1 and 15 to the consolidated financial statements, the Company recorded an impairment charge of $726 million for long-lived assets in connection with the Asset Group, for the year ended December 31, 2025. Long-lived assets are tested for impairment whenever events or changes in”). No longer listed: Goodwill Impairment Assessment - Teva API reporting unit. Same as last year: Sales Reserves and Allowances (“SR&A”) - Chargebacks and Medicaid in the United States
  • Cash from operations $1.6B vs net income $1.4B (FY ending Dec 31, 2025)
8 more checks with nothing to note
  • Inventory +5.7% ($3.0B to $3.2B) vs revenue +4.3% ($16.5B to $17.3B), +1.4 pts apart
  • Same auditor in both 10-Ks: Kesselman & Kesselman
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

14 paragraphs in Risk Factors that were not in the 10-K filed Feb 5, 2025. Quoted as filed.

All 14 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
    We also expect to continue to experience significant challenges to our global generics business. Governments worldwide continue to implement healthcare regulatory reforms aimed at reducing drug costs, including but not limited to, imposing price caps and other limits on generic medicine pricing and reimbursement policies, including as a…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
    Intense competition may adversely affect our ability to successfully develop and commercialize innovative medicines.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
    We have and will continue to implement changes to optimize our business operations and reallocate resources towards growth opportunities. As part of our Pivot to Growth strategy, in May 2025, we announced the Teva Transformation programs which are expected to generate cost savings for the Company, including by examining practices and…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
    Our adoption of artificial intelligence (“AI”) technologies introduces new risks and uncertainties Our adoption of AI technologies introduces new risks and uncertainties. These include potential inaccuracies or biases in AI outputs, cybersecurity vulnerabilities, and evolving global regulatory requirements governing AI use. Misuse or…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$14.9B$15.8B$16.5B$17.3B
Net income−$2.4B−$559.0M−$1.6B$1.4B
Operating cash flow$1.6B$1.4B$1.2B$1.6B
Free cash flow$1.0B$842.0M$749.0M$1.1B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$17.3B ▲ 4.3% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

12 filings in the last 30 days · SEC EDGAR

All filings
7 more

About the company

Teva Pharmaceutical Industries Ltd, Tel Aviv · from the 10-K filed Feb 3, 2026

Headquarters
Tel Aviv
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 3, 2026
Incorporated in
Israel

Employees, at the top of the page: "As of December 31, 2025, Teva’s global workforce consisted of 33,950 employees" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 3, 2026 (open at SEC), compared with the 10-K filed Feb 5, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEVA/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.